Search the Newsreel

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

The second-quarter 2026 reporting cycle for the Medical sector is picking up pace. The sector primarily comprises pharma/biotech and medical device companies. The earnings season for the Medical sector kicked off earlier this month when pharma bellwether Johnson & Johnson posted encouraging earnings results. …

Novartis dank starkem Ergebnis auf bestem Weg, Prognose fürs Gesamtjahr zu erreichen

CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight

The CAR T-cell therapy for NHL market is witnessing rapid expansion, driven by the transition from conventional chemo-immunotherapy to advanced cell-based treatment modalities. Strong efficacy in R/R disease, growing adoption in 2L and beyond, and the launch of emerging therapies such as Zamtocabtagene autoleucel …

Company News for July 22, 2026

Novartis AG's NVS shares grew 2.9% after reporting second-quarter 2026 revenues of $14.41 billion, beating the Zacks Consensus Estimate of $13.95 billion. Shares of General Motors Company GM gained 4.9% after reporting second-quarter 2026 earnings of $3.57 per share, beating the Zacks Consensus Estimate …

Novartis: Konsens-Beat ohne Prognoseanhebung - die Pipeline muss jetzt zeigen, was sie kann

Novartis (SWX:NOVN) Is Pushing AI Deeper Into Drug Discovery

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novartis (SWX:NOVN) CEO has outlined a bigger role for artificial intelligence across the company's research and development activities. The company is expanding investment …

AI is helping speed up the timelines of drug discovery, Novartis CEO says

Novartis stock (NVS) gets a lift higher on Tuesday after topping second quarter earnings estimates. Novartis CEO Vas Narasimhan sits down with Julie Hyman to talk more about the pharma giant's research into utilizing AI to aid in new drug discovery. Video Transcript 00:00 …

Novartis Profit Beats Estimates as Entresto Sales Plunge 50%

This article first appeared on GuruFocus. Novartis AG (NYSE:NVS), a Swiss pharmaceutical company focused on innovative medicines, reported stronger-than-expected second-quarter results as newer cancer treatments helped offset declining sales from its former blockbuster heart drug Entresto. Earnings excluding certain items remained unchanged at $5.94 …

Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well

Swiss pharma giant Novartis AG NVS reported second-quarter core earnings per share (excluding one-time charges) of $2.41, which comfortably beat the Zacks Consensus Estimate of $2.20. The figure was, however, down from $2.42 reported a year ago due to lower core net income. Revenues …

Novartis Q2 Earnings Call Highlights

Key Points Interested in Novartis AG? Here are five stocks we like better. Novartis returned to sales growth in Q2 2026, with net sales up 1% in constant currency to $14.4 billion and free cash flow of $5.6 billion. The company reaffirmed its full-year …

Novartis Is On The Rise. But So, Too, Are Its Generic Rivals.

Novartis stock popped Tuesday on a solid second-quarter report, despite feeling continued heat from generic rivals for big-name drugs. Continue Reading

Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Novartis (NVS) reported revenue of $14.41 billion, up 2.5% over the same period last year. EPS came in at $2.41, compared to $2.42 in the year-ago quarter. The reported revenue represents a surprise of +3.3% over the Zacks …

Novartis Q2 2026 earnings beat as cancer, MS drugs drive growth

Novartis reported second-quarter net sales of $14.4 billion on Tuesday, up 3% in dollar terms and 1% in constant currencies, as strong demand for cancer and multiple sclerosis treatments helped the Swiss drugmaker return to sales growth despite a steep drop in its top-selling …

U.S. stocks set for higher open as strong earnings boost market sentiment: Dow Jones, S&P, Nasdaq, Wall Street Futures

Wall Street bull ©Shutterstock Earnings optimism supports pre-market gains U.S. stock futures pointed to a firmer open on Tuesday as investors looked to recover from the previous session's decline, with upbeat corporate earnings encouraging buying across several sectors. Market sentiment improved after a series …

Novartis Bounds For Buy Point. Why Shares Are On The Rise.

Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx. Continue Reading

Novartis Earnings Beat, Cash Flow Weakens

This article first appeared on GuruFocus. Novartis (NYSE:NVS) beat second-quarter expectations on both revenue and earnings, while reaffirming its full-year 2026 outlook despite weaker free cash flow. The Swiss drugmaker reported adjusted earnings of $2.41 per share, beating estimates by $0.26. Revenue rose 2.6% …

Novartis Q2 profits recover as revenue mantle passes to newer medicines

Despite a lacklustre start to the year, Novartis seems to have overcome its financial slump, reporting operating profits in Q2 that exceeded analyst expectations. The Swiss drugmaker's core operating income for the quarter was $5.94bn, representing flat year-over-year growth. However, this was ahead of …

Novartis returns to sales growth in Q2 as newer medicines offset generic pressure (NVS)

Researcher with pipette ©National Institutes of Health New therapies drive quarterly revenue increase Novartis AG (NYSE:NVS) reported higher second-quarter sales on Tuesday, with strong demand for its newer medicines helping to offset the continued impact of generic competition and supporting the company's decision to …

Novartis climbs on upbeat drug sales as key readouts loom

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Novartis said second-quarter sales inched upward, beating analyst expectations for a decline as demand for newer products helped offset generic …

Novartis says buoyed by new treatments in second quarter

Basel-based Novartis is facing the expiry of patents for a number of its products (GABRIEL MONNET) Swiss pharmaceuticals giant Novartis said Tuesday that group sales exceeded expectations in the second quarter of 2026, on the back of a range of new products. Novartis said …

Earnings Snapshot: Novartis Q2 tops earnings and revenue estimates; full-year 2026 outlook reaffirmed

[https://static.seekingalpha.com/uploads/2026/7/21/saupload_Screenshot_2026-07-21_120006.png] MORE ON NOVARTIS * Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon [https://seekingalpha.com/article/4920275-novartis-pipeline-building-continues-pelacarsen-readout-coming-soon] * Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts [https://seekingalpha.com/article/4919803-novartis-hold-on-continued-generic-erosion-need-for-2nd-half-2026-catalysts] * Novartis Plays Long Game With Antares Deal - Meaning Near-Term Upside Unlikely [https://seekingalpha.com/a

Novartis beats top-line and bottom-line estimates; reaffirms FY26 outlook

* Novartis press release [https://www.novartis.com/sites/novartis_com/files/q2-2026-media-release-en.pdf] (NVS [https://seekingalpha.com/symbol/NVS]): Q2 Non-GAAP EPS of $2.41 beats by $0.26. * Revenue of $14.41B (+2.6% Y/Y) beats by $350M. * Q2 free cash flow was USD 5.6 billion (-12% USD). * FULL-YEAR 2026 GUIDANCE REAFFIRMED: Net sales expected to …

Novartis Q2 Profit Drops, Net Sales Rise; Reaffirms FY26 Guidance

(RTTNews) - Swiss pharmaceutical major Novartis AG (NVS, NOVN.SW) reported Tuesday lower profit in its second quarter, despite higher net sales and volume growth. Further, the company said it continues to expect fiscal 2026 core operating income to decline low single-digit and net sales …

Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed

Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD) Sales growth driven by priority brands including Kisqali (+43% cc), Kesimpta (+32% cc), Scemblix (+89% cc), …

Novartis Earnings Preview: Can New Medicines Offset Generic Pressure and Growing U.S. Pricing Risks?

Novartis Enters Q2 After Weathering One of the Biggest Patent Cliffs in Its History Although first-quarter revenue fell 1% year over year to $13.1 billion, or 5% at constant currencies, the results largely matched management's expectations as several blockbuster medicines lost patent protection in …

Novartis faces drug pipeline test with valuation premium in focus

By Bhanvi Satija LONDON, July 20 (Reuters) - Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year seen as vital to justifying the Swiss ‌drugmaker's premium valuation. Analysts say …

Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?

Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. This traditional approval converts the drug's August 2024 accelerated approval, which …